0001654954-21-008635.txt : 20210809 0001654954-21-008635.hdr.sgml : 20210809 20210809161611 ACCESSION NUMBER: 0001654954-21-008635 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20210809 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210809 DATE AS OF CHANGE: 20210809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Celcuity Inc. CENTRAL INDEX KEY: 0001603454 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38207 FILM NUMBER: 211156690 BUSINESS ADDRESS: STREET 1: 16305 36TH AVENUE N STREET 2: SUITE 100 CITY: MINNEAPOLIS STATE: MN ZIP: 55446 BUSINESS PHONE: 763-392-0767 MAIL ADDRESS: STREET 1: 16305 36TH AVENUE N STREET 2: SUITE 100 CITY: MINNEAPOLIS STATE: MN ZIP: 55446 FORMER COMPANY: FORMER CONFORMED NAME: Celcuity LLC DATE OF NAME CHANGE: 20140324 8-K 1 celc_8k.htm CURRENT REPORT celc_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 9, 2021

 

Celcuity Inc.

(Exact name of Registrant as Specified in its Charter)

    

Delaware

 

001-38207

 

82-2863566

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

16305 36th Avenue North; Suite 100
Minneapolis, Minnesota 55446

(Address of Principal Executive Offices and Zip Code)

 

(763) 392-0767

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value per share

 

CELC

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

    

Item 2.02. Results of Operations and Financial Condition.

 

On August 9, 2021, Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the second quarter ended June 30, 2021. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

 

 

Description

 

 

99.1

 

Press release dated August 9, 2021

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 9, 2021

 

 

CELCUITY INC.

    
By:

/s/ Brian F. Sullivan

 

 

Brian F. Sullivan 
  

Chairman and Chief Executive Officer

 

 

 

 

 EX-99.1 2 celc_ex991.htm PRESS RELEASE celc_ex991.htm

  EXHIBIT 99.1

 

     

Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

 

 

-

Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities

 

 

 

 

-

After follow-on offering, Celcuity had approximately $94.4 million of cash on hand

 

 

 

 

-

Expanded clinical development and clinical operations capabilities with appointment of two new senior executives and the addition of other key team members

 

 

 

 

-

In a Phase 1 study evaluating gedatolisib combined with paclitaxel and carboplatin, 65% of patients (11/17) had an objective response, including three complete responses

 

 

 

 

-

Management to host webcast and conference call today, August 9, 2021, at 4:30 p.m. ET / 1:30 p.m. PT

    

MINNEAPOLIS, August 9, 2021 — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced financial results for the second quarter ended June 30, 2021 and summarized recent business progress.

 

“Celcuity’s recent follow-on equity offering strengthens our balance sheet and provides additional funding to support clinical development activities for the advancement of gedatolisib, a potential first-in-class PI3K/mTOR inhibitor,” said Brian Sullivan, CEO and co-founder of Celcuity. “We are also very excited about the progress we made expanding our clinical development and clinical operations teams. This positions us well to initiate, subject to feedback from the FDA, a Phase 2/3 clinical trial evaluating gedatolisib in combination with palbociclib and an endocrine therapy in patients with ER+/HER2- advanced or metastatic breast cancer in the first half of 2022.”

 

Second Quarter 2021 Business Highlights and Other Recent Developments

 

 

·

 In early April, Celcuity entered into a worldwide licensing agreement with Pfizer for the exclusive right to develop and commercialize gedatolisib.

 

 

 

 

·

 Celcuity closed two significant financings to support development of gedatolisib. In early April, Celcuity entered into a debt financing agreement with Innovatus Life Sciences Lending Fund I, LP to provide up to $25.0 million in term loans with the first tranche of $15.0 million funded at closing. In early July, Celcuity completed a follow-on public offering that raised gross proceeds of approximately $56.3 million.

  

 

 

   

 

·

 In April, Celcuity presented results of studies evaluating gedatolisib, inavolisib (a PI3K-α inhibitor), and navitoclax (a BCL inhibitor) in breast and ovarian patient tumors in two posters at the American Association for Cancer Research (AACR) Annual Meeting. The results showed that gedatolisib inhibited nine times more signaling test activity in tumors with hyperactive RAS network signaling, on average, than inavolisib, when evaluated at equal concentrations with the CELsignia test.

 

 

 

 

·

 In June, Celcuity announced the addition of Igor Gorbatchevsky, MD, as VP of Clinical Development and Jill Krause as VP of Clinical Operations to Celcuity’s leadership team. Dr. Gorbatchevsky has over two decades of hands-on oncology drug development experience, including successful regulatory IND and NDA/BLA filings across several drug classes. Ms. Krause has deep clinical operations expertise, including over nine years of experience managing and executing trials in breast cancer. Since joining Celcuity, Dr. Gorbatchevsky and Ms. Krause have each added key members to their respective teams.

 

 

 

 

·

 In July, results from a 17-patient Phase 1 study that evaluated the safety and preliminary activity of gedatolisib combined with carboplatin and paclitaxel were published in the journal, Clinical Cancer Research1. The study was designed to explore the hypothesis that inhibition of the PI3K/mTOR pathway can promote sensitivity to platinum-based treatment. The objective response rate (ORR) was 65% (11/17) patients: eight partial responses (PR) and three complete responses (CR) were reported. The stable disease rate was 17% (3/17). Promising results were observed in patients with advanced clear cell ovarian carcinoma (CCOC), a tumor type with poor prognosis generally considered to be chemo resistant. The ORR in patients with CCOC was 80% (8/10), of which 3/10 (30%) reported a CR. Among nine previously platinum-treated patients, 45% (4/9) had a PR (two patients with CCOC, one low grade serous ovarian cancer and one NSCLC). The drug combination was found to be tolerable with a manageable safety profile.

     

Second Quarter 2021 Financial Results

 

Unless otherwise stated, all comparisons are for the second quarter ended June 30, 2021, compared to the second quarter ended June 30, 2020.

 

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and related notes on Form 10-Q for the second quarter ended June 30, 2021.

 

Total operating expenses were $13.6 million for the second quarter of 2021, compared to $2.2 million for the second quarter of 2020.

 

Research and development (R&D) expenses were $13.1 million for the second quarter of 2021, compared to $1.8 million for the second quarter of 2020. The increase during the second quarter of 2021 compared to the prior year, primarily resulted from a $10.0 million upfront license fee related to the execution of the Pfizer license agreement, which included $5.0 million of non-cash expense for the issuance of common stock. The remaining increase in expenses related to compensation, clinical validation and laboratory studies and legal expenses.

 

General and administrative (G&A) expenses were $0.6 million for the second quarter of 2021, compared to $0.4 million for the second quarter of 2020. The increase in the second quarter of 2021 arose primarily from higher professional fees associated with being a public company, director and officer insurance and non-cash stock-based compensation.

 

 

 

   

Net loss for the second quarter of 2021 was $14.0 million, or $1.11 loss per share, compared to a net loss of $2.2 million, or $0.21 loss per share, for the second quarter of 2020. Non-GAAP adjusted net loss for the second quarter of 2021 was $8.3 million, or $0.66 loss per share, compared to non-GAAP adjusted net loss of $1.8 million, or $0.17 loss per share, for the second quarter of 2020. Non-GAAP adjusted net loss excludes stock-based compensation expense, issuance of common stock and non-cash interest. Because these items have no impact on Celcuity’s cash position, management believes non-GAAP adjusted net loss better enables Celcuity to focus on cash used in operations. For a reconciliation of financial measures calculated in accordance with generally accepted accounting principles in the United States (GAAP) to non-GAAP financial measures, please see the financial tables at the end of this press release.

 

Net cash used in operating activities for the second quarter of 2021 was $7.6 million, compared to $1.6 million for the second quarter of 2020.

 

At June 30, 2021, Celcuity had cash and cash equivalents of $41.6 million, compared to cash and cash equivalents of $11.6 million at December 31, 2020. On April 8, 2021, Celcuity paid an upfront license fee of $5.0 million in conjunction with the Pfizer gedatolisib license agreement and received $14.4 million of net proceeds from a debt financing agreement. On July 1, 2021, Celcuity completed a follow-on equity offering of common stock that resulted in gross proceeds of approximately $56.3 million. After the follow-on offering, Celcuity had approximately $94.4 million of cash on hand.

 

Anticipated Milestones

 

Celcuity expects to achieve the following potential milestones over the next twelve months:

 

 

·

 Announce an additional clinical trial collaboration utilizing the CELsignia platform in the second half of 2021.

 

 

 

 

·

 Initiate a Phase 2/3 clinical trial for gedatolisib in patients with ER+/HER2- metastatic breast cancer in the first half of 2022, subject to feedback from the FDA.

 

 

 

 

·

 Provide an update on the lifecycle development plan for gedatolisib in the first half of 2022.

 

 

 

 

·

 Provide interim results from the FACT-1 and FACT-2 trials in late 2021 or early 2022.

  

Webcast and Conference Call Information

 

The Celcuity management team will host a webcast/conference call at 4:30 p.m. ET today to discuss the second quarter financial results and provide a corporate update. To participate in the teleconference, domestic callers should dial 1-844-369-8770 and international callers should dial 862-298-0840. A live webcast presentation can also be accessed using this weblink: https://www.webcaster4.com/Webcast/Page/2678/42136. A replay of the webcast will be available on the Celcuity website following the live event.

 

 

 

   

About Celcuity

 

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic and therapeutic strategy. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Its therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

 

Forward-Looking Statements

 

This press release contains statements that constitute “forward-looking statements” that involve risks and uncertainties including, but not limited to, expected FDA feedback for Celcuity’s planned gedatolisib clinical trials, the timing, costs and results of Celcuity’s expected clinical trials, Celcuity’s expectations with respect to planned clinical collaborations, clinical trials and the timing and content of updates on the gedatolisib life cycle development plan and results of ongoing clinical trials. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends” or “continue,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Celcuity, which include, but are not limited to, the unknown impact of the COVID-19 pandemic on Celcuity’s business and those other risks set forth in the Risk Factors section in Celcuity’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission on February 16, 2021 and in Exhibit 99.4 to Celcuity’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2021. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

 

1 Colombo, I. et al., Phase 1 Dose-Escalation Study of the dual PI3K-mTORC1/2 inhibitor Gedatolisib in combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. Clin Cancer Res July 15 2021 DOI: 10.1158/1078-0432.CCR-21-1402

 

Contacts:

 

Celcuity Inc.

Brian Sullivan, bsullivan@celcuity.com

Vicky Hahne, vhahne@celcuity.com

 

Westwicke ICR
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

 

  

 

    

Celcuity Inc.

 Condensed Balance Sheets

 

 

 

June 30, 2021

 

 

December 31, 2020

 

 

 

(unaudited)

 

 

 

Assets

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

 $ 41,638,623

 

 

 $ 11,637,911

 

Deposits

 

 

 22,009

 

 

 

 22,009

 

Deferred transaction costs

 

 

 121,307

 

 

 

 -

 

Payroll tax receivable

 

 

 190,000

 

 

 

 190,000

 

Prepaid assets

 

 

 279,544

 

 

 

 317,040

 

Total current assets

 

 

 42,251,483

 

 

 

 12,166,960

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

 415,080

 

 

 

 558,876

 

Operating lease right-of-use assets

 

 

 142,766

 

 

 

 230,911

 

Total Assets

 

 $ 42,809,329

 

 

 $ 12,956,747

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity:

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 $ 647,172

 

 

 $ 217,377

 

Finance lease liabilities

 

 

 5,830

 

 

 

 5,810

 

Operating lease liabilities

 

 

 153,684

 

 

 

 187,518

 

Accrued expenses

 

 

 729,672

 

 

 

 774,612

 

Total current liabilities

 

 

 1,536,358

 

 

 

 1,185,317

 

Finance lease liabilities

 

 

 5,379

 

 

 

 8,299

 

Operating lease liabilities

 

 

 -

 

 

 

 60,861

 

Note payable, non-current

 

 

 14,233,068

 

 

 

 -

 

Total Liabilities

 

 

 15,774,805

 

 

 

 1,254,477

 

Total Stockholders’ Equity

 

 

 27,034,524

 

 

 

 11,702,270

 

Total Liabilities and Stockholders’ Equity

 

 $ 42,809,329

 

 

 $ 12,956,747

 

 

 

 

    

Celcuity Inc.

 Condensed Statements of Operations

 (unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 $ 13,070,108

 

 

 $ 1,766,227

 

 

 $ 15,306,451

 

 

 $ 3,613,641

 

General and administrative

 

 

 573,360

 

 

 

 447,714

 

 

 

 1,128,787

 

 

 

 911,113

 

Total operating expenses

 

 

 13,643,468

 

 

 

 2,213,941

 

 

 

 16,435,238

 

 

 

 4,524,754

 

Loss from operations

 

 

 (13,643,468 )

 

 

 (2,213,941 )

 

 

 (16,435,238 )

 

 

 (4,524,754 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

 (391,187 )

 

 

 (31 )

 

 

 (391,210 )

 

 

 (64 )

Interest income

 

 

 1,803

 

 

 

 11,983

 

 

 

 2,191

 

 

 

 75,834

 

Loss on sale of fixed assets

 

 

 -

 

 

 

 -

 

 

 

 (263 )

 

 

 -

 

Other income (expense), net

 

 

 (389,384 )

 

 

 11,952

 

 

 

 (389,282 )

 

 

 75,770

 

Net loss before income taxes

 

 

 (14,032,852 )

 

 

 (2,201,989 )

 

 

 (16,824,520 )

 

 

 (4,448,984 )

Income tax benefits

 

 

 -

 

 

 

 -

 

 

 

 -

 

 

 

 -

 

Net loss

 

 $ (14,032,852 )

 

 $ (2,201,989 )

 

 $ (16,824,520 )

 

 $ (4,448,984 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

 

 $ (1.11 )

 

 $ (0.21 )

 

 $ (1.42 )

 

 $ (0.43 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

 12,610,917

 

 

 

 10,260,234

 

 

 

 11,845,758

 

 

 

 10,257,111

 

  

 

 

  

Cautionary Statement Regarding Non-GAAP Financial Measures

 

This press release contains references to non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Management believes these non-GAAP financial measures are useful supplemental measures for planning, monitoring, and evaluating operational performance as they exclude stock-based compensation expense, issuance of common stock and non-cash interest from net loss and net loss per share. Management excludes these items because they do not impact Celcuity’s cash position, which management believes better enables Celcuity to focus on cash used in operations. However, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share are not recognized measures under GAAP and do not have a standardized meaning prescribed by GAAP. As a result, management’s method of calculating non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may differ materially from the method used by other companies. Therefore, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share may not be comparable to similarly titled measures presented by other companies. Investors are cautioned that non-GAAP adjusted net loss and non-GAAP adjusted net loss per share should not be construed as alternatives to net loss, net loss per share or other statements of operations data (which are determined in accordance with GAAP) as an indicator of Celcuity’s performance or as a measure of liquidity and cash flows.
 

 

 

   

Celcuity Inc.

Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and

GAAP Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss

 

 $ (14,032,852 )

 

 $ (2,201,989 )

 

 $ (16,824,520 )

 

 $ (4,448,984 )

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development (1)

 

 

 328,077

 

 

 

 265,446

 

 

 

 583,258

 

 

 

 558,562

 

General and administrative (2)

 

 

 212,240

 

 

 

 157,747

 

 

 

 406,157

 

 

 

 329,280

 

Issuance of common stock, licensing agreement (3)

 

 

 5,000,000

 

 

 

 -

 

 

 

 5,000,000

 

 

 

 -

 

Non-cash interest expense (4)

 

 

 174,968

 

 

 

 -

 

 

 

 174,968

 

 

 

 -

 

Non-GAAP adjusted net loss

 

 $ (8,317,567 )

 

 $ (1,778,796 )

 

 $ (10,660,137 )

 

 $ (3,561,142 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss per share - basic and diluted

 

 $ (1.11 )

 

 $ (0.21 )

 

 $ (1.42 )

 

 $ (0.43 )

Adjustment to net loss (as detailed above)

 

 

 0.45

 

 

 

 0.04

 

 

 

 0.52

 

 

 

 0.09

 

Non-GAAP adjusted net loss per share

 

 $ (0.66 )

 

 $ (0.17 )

 

 $ (0.90 )

 

 $ (0.34 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

 12,610,917

 

 

 

 10,260,234

 

 

 

 11,845,758

 

 

 

 10,257,111

 

 

(1) To reflect a non-cash charge to operating expense for Research and Development stock-based compensation.

(2) To reflect a non-cash charge to operating expense for General and Administrative stock-based compensation.

(3) To reflect a non-cash charge to operating expense for the issuance of common stock related to a licensing agreement.

(4) To reflect a non-cash charge to other expense for amortization of debt issuance and discount costs and PIK interest related to the issuance of a note payable.

 

 

 

 

 GRAPHIC 3 celc_ex991img1.jpg IMAGE begin 644 celc_ex991img1.jpg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end EX-101.SCH 4 celc-20210809.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 celc-20210809_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 celc-20210809_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 celc-20210809_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Ex Transition Period Entity Incorporation State Country Code Entity File Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Trading Symbol Security Exchange Name EX-101.PRE 8 celc-20210809_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 celc_8k_htm.xml IDEA: XBRL DOCUMENT 0001603454 2021-08-09 2021-08-09 iso4217:USD shares iso4217:USD shares 0001603454 false 8-K 2021-08-09 Celcuity Inc. DE 001-38207 82-2863566 16305 36th Avenue North Suite 100 Minneapolis MN 55446 763 392-0767 false false false false Common Stock, $0.001 par value per share CELC NASDAQ true true XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 09, 2021
Cover [Abstract]  
Entity Registrant Name Celcuity Inc.
Entity Central Index Key 0001603454
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company true
Document Period End Date Aug. 09, 2021
Entity Ex Transition Period true
Entity Incorporation State Country Code DE
Entity File Number 001-38207
Entity Tax Identification Number 82-2863566
Entity Address Address Line 1 16305 36th Avenue North
Entity Address Address Line 2 Suite 100
Entity Address City Or Town Minneapolis
Entity Address State Or Province MN
Entity Address Postal Zip Code 55446
City Area Code 763
Local Phone Number 392-0767
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol CELC
Security Exchange Name NASDAQ
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://celc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports celc_8k.htm celc-20210809.xsd celc-20210809_cal.xml celc-20210809_def.xml celc-20210809_lab.xml celc-20210809_pre.xml celc_ex991.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "celc_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "celc-20210809_cal.xml" ] }, "definitionLink": { "local": [ "celc-20210809_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "celc_8k.htm" ] }, "labelLink": { "local": [ "celc-20210809_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "celc-20210809_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "celc-20210809.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "celc", "nsuri": "http://celc.com/20210809", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celc_8k.htm", "contextRef": "From2021-08-09to2021-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://celc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celc_8k.htm", "contextRef": "From2021-08-09to2021-08-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://celc.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001654954-21-008635-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-21-008635-xbrl.zip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�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